CN105829315B - 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类 - Google Patents

可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类 Download PDF

Info

Publication number
CN105829315B
CN105829315B CN201480069437.9A CN201480069437A CN105829315B CN 105829315 B CN105829315 B CN 105829315B CN 201480069437 A CN201480069437 A CN 201480069437A CN 105829315 B CN105829315 B CN 105829315B
Authority
CN
China
Prior art keywords
methyl
dichlorophenyl
pyrimidin
amino
dihydropyrimido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480069437.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105829315A (zh
Inventor
蒂莫西·哈里森
格雷厄姆·特雷维特
彼得·罗宾·休伊特
科林·罗德里克·奥多德
弗兰克·布尔坎普
安德鲁·约翰·威尔金森
史蒂文·D·谢泼德
休斯·米尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of CN105829315A publication Critical patent/CN105829315A/zh
Application granted granted Critical
Publication of CN105829315B publication Critical patent/CN105829315B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480069437.9A 2013-12-19 2014-12-19 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类 Active CN105829315B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1322602.2 2013-12-19
GBGB1322602.2A GB201322602D0 (en) 2013-12-19 2013-12-19 Pharmaceutical compounds
PCT/GB2014/053793 WO2015092431A1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Publications (2)

Publication Number Publication Date
CN105829315A CN105829315A (zh) 2016-08-03
CN105829315B true CN105829315B (zh) 2019-03-08

Family

ID=50071157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480069437.9A Active CN105829315B (zh) 2013-12-19 2014-12-19 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类

Country Status (28)

Country Link
US (1) US9850247B2 (https=)
EP (1) EP3083625B1 (https=)
JP (1) JP6437559B2 (https=)
KR (1) KR102405462B1 (https=)
CN (1) CN105829315B (https=)
AU (1) AU2014369457B2 (https=)
BR (1) BR112016014151B1 (https=)
CA (1) CA2933755C (https=)
CY (1) CY1120035T1 (https=)
DK (1) DK3083625T3 (https=)
ES (1) ES2650013T3 (https=)
GB (1) GB201322602D0 (https=)
HR (1) HRP20180080T1 (https=)
HU (1) HUE037908T2 (https=)
IL (1) IL245672B (https=)
LT (1) LT3083625T (https=)
MX (1) MX371108B (https=)
NO (1) NO3083625T3 (https=)
NZ (1) NZ720178A (https=)
PL (1) PL3083625T3 (https=)
PT (1) PT3083625T (https=)
RS (1) RS56731B1 (https=)
RU (1) RU2691105C1 (https=)
SG (1) SG11201603814TA (https=)
SI (1) SI3083625T1 (https=)
SM (1) SMT201800020T1 (https=)
WO (1) WO2015092431A1 (https=)
ZA (1) ZA201603337B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364247B2 (en) * 2015-04-21 2019-07-30 Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Preparation and use of novel protein kinase inhibitors
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
US10703759B2 (en) 2016-11-16 2020-07-07 Impact Therapeutics, Inc 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
WO2018133829A1 (zh) * 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
US11345710B2 (en) 2017-07-10 2022-05-31 Impact Therapeutics (Shanghai), Inc Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
DK3712150T3 (da) 2017-11-01 2024-07-29 Wuxi Biocity Biopharmaceutics Co Ltd Makrocyklisk forbindelse, der tjener som wee1-hæmmer, og anvendelser deraf
EP3758706A4 (en) 2018-02-28 2021-11-24 The Regents Of The University Of Colorado WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THEREOF
AU2019348120A1 (en) * 2018-09-27 2021-05-06 Betta Pharmaceuticals Co., Ltd FGFR4 inhibitor and use thereof
JP7481336B2 (ja) 2018-10-26 2024-05-10 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用
EP3902805A4 (en) 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
EP3943496A4 (en) 2019-03-22 2022-05-18 Shouyao Holdings (Beijing) Co., Ltd. Wee1 inhibitor and preparation and use thereof
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
US20220162229A1 (en) * 2019-04-09 2022-05-26 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US20220168313A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN113784968B (zh) 2019-04-30 2024-03-15 无锡智康弘义生物科技有限公司 Wee1抑制剂化合物的晶型及其应用
CN112142763B (zh) * 2019-06-28 2024-01-26 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
US12522607B2 (en) 2020-06-17 2026-01-13 Wigen Biomedicine Technology (shanghai) Co., Ltd. Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors
WO2022072336A1 (en) * 2020-10-01 2022-04-07 University Of Washington Drug-like molecules and methods for the therapeutic targeting of microrna-21
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
JP2024502231A (ja) * 2020-12-18 2024-01-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｎａｖ１．８電位依存性ナトリウムチャネルを阻害するためおよびＮａｖ１．８介在疾患を治療するために有用な化学化合物
JP2023554430A (ja) * 2020-12-18 2023-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｎａｖ１．８阻害剤としての含窒素２，３－ジヒドロキナゾリノン化合物
AU2022265032A1 (en) 2021-04-30 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
BR112023025403A2 (pt) 2021-06-25 2024-02-20 Korea Res Inst Chemical Tech Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
WO2013059485A1 (en) * 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1727819A1 (en) 2004-03-15 2006-12-06 F.Hoffmann-La Roche Ag Novel dichloro-phenyl-pyrido¬2,3-d|pyrimidine derivatives, their manufacture and use as pharmaceutical agents
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
JP5411847B2 (ja) 2007-04-25 2014-02-12 Ｍｓｄ株式会社 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
ES2608940T3 (es) 2007-06-15 2017-04-17 Msd K.K. Derivado de bicicloanilina
EP2213673B1 (en) 2007-10-23 2013-06-05 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EP2376493B1 (en) 2008-12-12 2016-10-05 Msd K.K. Dihydropyrimidopyrimidine derivative
CA2745959A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
PE20140421A1 (es) * 2010-12-06 2014-04-26 Glaxo Group Ltd COMPUESTOS DERIVADOS DE PIRIMIDINONA COMO INHIBIDORES DE Lp-PLA2
TWI532742B (zh) * 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
US8716297B2 (en) 2011-07-15 2014-05-06 Abbvie Inc. Chemical entities to be used for Wee1 inhibition for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
WO2013059485A1 (en) * 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法

Also Published As

Publication number Publication date
CA2933755C (en) 2023-01-31
US9850247B2 (en) 2017-12-26
HRP20180080T1 (hr) 2018-03-09
US20160318936A1 (en) 2016-11-03
MX371108B (es) 2020-01-17
BR112016014151B1 (pt) 2023-01-17
LT3083625T (lt) 2017-12-27
SMT201800020T1 (it) 2018-05-02
RU2691105C1 (ru) 2019-06-11
EP3083625B1 (en) 2017-11-01
JP2017500335A (ja) 2017-01-05
SG11201603814TA (en) 2016-07-28
EP3083625A1 (en) 2016-10-26
ES2650013T3 (es) 2018-01-16
CN105829315A (zh) 2016-08-03
PL3083625T3 (pl) 2018-03-30
CA2933755A1 (en) 2015-06-25
RS56731B1 (sr) 2018-03-30
MX2016007801A (es) 2016-09-07
SI3083625T1 (en) 2018-03-30
KR20160098499A (ko) 2016-08-18
AU2014369457A1 (en) 2016-06-09
ZA201603337B (en) 2018-07-25
PT3083625T (pt) 2018-02-06
WO2015092431A1 (en) 2015-06-25
KR102405462B1 (ko) 2022-06-03
GB201322602D0 (en) 2014-02-05
CY1120035T1 (el) 2018-12-12
IL245672B (en) 2021-10-31
DK3083625T3 (en) 2017-12-18
NZ720178A (en) 2022-05-27
JP6437559B2 (ja) 2018-12-12
AU2014369457B2 (en) 2018-08-09
IL245672A0 (en) 2016-06-30
NO3083625T3 (https=) 2018-03-31
RU2016123363A (ru) 2018-01-25
HUE037908T2 (hu) 2018-09-28
BR112016014151A2 (https=) 2017-08-08

Similar Documents

Publication Publication Date Title
CN105829315B (zh) 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类
JP7073359B2 (ja) ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体
CN107253963B (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法
TWI624467B (zh) 選擇性經取代之喹啉化合物
CN102548557B (zh) 用于降低β-淀粉状蛋白生成的化合物
CN104470925B (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
WO2023217230A1 (zh) 驱动蛋白kif18a抑制剂及其应用
WO2020156437A1 (zh) Akt抑制剂
WO2024153155A1 (zh) 双杂环wrn抑制剂、其制备方法及其应用
CN112135818A (zh) 4-羟基哌啶衍生物及其作为泛素特异性蛋白酶19(usp19)的抑制剂的用途
WO2024175024A1 (zh) 作为CDKs抑制剂的新型并杂环类新化合物及其应用
CN115485276B (zh) 氘代akt激酶抑制剂
HK1227877B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
HK1227877A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
HK1223089A1 (zh) 激酶抑制剂及其用途
HK1201268A1 (en) Bicyclic piperazine compounds
HK1201268B (zh) 二环哌嗪化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant